Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Background Patients with acute myeloid leukaemia (AML) positive for internal tandem
duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …